Glenmark Pharmaceuticals Share Price
2432.60-26.40 (-1.07%)
+21.36% past 1 Year
News
Glenmark Pharma unit launches US generic calcium gluconate injectable
Equity
GLENMARK
Glenmark Pharma gets US FDA nod for fluticasone nasal spray sales
Equity
GLENMARK
Glenmark highlights significant revenue dependence on US market for sales mix
Equity
GLENMARK
Glenmark sets FY27 margin guidance band, targets 21-22 percent range
Equity
GLENMARK
Glenmark estimates quarterly US sales above Rs 10.00 crores threshold
Equity
GLENMARK
Glenmark sees strong upside in US sales trajectory, boosting growth outlook
Equity
GLENMARK
Glenmark Pharma targets double-digit India growth and debt-free balance sheet
Equity
GLENMARK
Glenmark Pharma guides for steady operating margins despite cost pressures
Equity
GLENMARK
Glenmark Pharma targets stronger Europe growth with sustained R&D investments
Equity
GLENMARK
Glenmark Pharma flags over 18 percent annual growth led by North America recovery
Equity
GLENMARK
Glenmark Pharma reports strong Q1 EBITDA growth and margin expansion YoY
Equity
GLENMARK
Glenmark Pharma reports strong Q1 revenue growth on year-over-year basis
Equity
GLENMARK
Glenmark Pharma Q1 consolidated net profit surges sharply year-on-year
Equity
GLENMARK
Glenmark Pharma Q1 consolidated PBT rises sharply on strong YoY growth
Equity
GLENMARK
Glenmark Pharma unit launches generic Sugammadex injection in US market
Equity
GLENMARK
Glenmark Pharma outlines major shift toward innovation-led revenue mix over medium term
Equity
GLENMARK
Glenmark Pharmaceuticals schedules Q1 FY27 earnings call on August 3, 2026
Equity
GLENMARK
Glenmark Pharma gains US FDA nod to extend Ryaltris paediatric use
Equity
GLENMARK
Glenmark Pharma sees Rs 16.97 crores NSE block trade at premium price
Equity
GLENMARK
Glenmark US arm launches generic Olanzapine injection targeting USD 25.4 million market
Equity
GLENMARK